Results 211 to 220 of about 11,219 (248)

Telitacicept as a New Therapeutic Avenue for Generalized Myasthenia Gravis and Thymoma-Associated Myasthenia Gravis

Journal of Neuroimmune Pharmacology
Generalized myasthenia gravis (gMG) is an antibody mediated autoimmune neuromuscular junction disorder characterized by muscle weakness and fatigue as well as acetylcholine receptor antibody (AChR-Ab) as the main presence. A proportion of patients fail to achieve minimal symptom expression (MSE), furthermore 10-20% of them develop into refractory under
Ying, Zhu, Benqiao, Wang, Chunxiang, Hu, Ruixia, Zhu   +3 more
openaire   +2 more sources

Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

NEJM Evidence, 2022
BACKGROUND: Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating autoimmune disease. Activation of the complement system by autoantibodies against the postsynaptic acetylcholine receptor (AChR) leads to destruction of the postsynaptic membrane and disruption of neuromuscular transmission.
Tuan, Vu, Andreas, Meisel, Renato, Mantegazza, Djillali, Annane, Masahisa, Katsuno, Rasha, Aguzzi, Ahmed, Enayetallah, Kathleen N, Beasley, Nishi, Rampal, James F, Howard   +9 more
openaire   +2 more sources

Corticotropin in Generalized Myasthenia Gravis

JAMA, 1966
The effect of short, intensive courses of corticotropin (100 units intravenously, daily for ten days) was studied in patients with generalized myasthenia gravis. A decrease in strength and response to anticholinesterase medication occurred during 21 of 22 courses in seven of eight patients.
openaire   +1 more source

Frequency of seronegativity in adult‐acquired generalized myasthenia gravis

Muscle & Nerve, 2007
AbstractWe determined the prevalence of muscle acetylcholine receptor (AChR) antibodies in patients with adult‐acquired generalized myasthenia gravis (MG), the seroconversion rate at 12 months, and the prevalence of muscle‐specific tyrosine kinase (MuSK) antibody among persistently seronegative patients.
Lennon, VA, Chan, KH, Harper, CM, Lachance, DH   +3 more
openaire   +4 more sources

Comment: Methotrexate for patients with generalized myasthenia gravis

Neurology, 2016
Methotrexate (MTX) has long been a favorite drug of rheumatologists for treating rheumatoid arthritis, inflammatory myositis, and other autoimmune diseases. Why not myasthenia gravis (MG) as well? Reports of positive results of MTX treatment of MG led to this gold standard double-blind randomized controlled trial of MTX in patients with MG. The article
openaire   +2 more sources

Correlation of C3 level with severity of generalized myasthenia gravis

Muscle & Nerve, 2009
AbstractAcute exacerbation of generalized myasthenia gravis (GMG) can cause swallowing impairment, respiratory failure, or death. It is important to identify immunological factors that might be regarded reliably as an index of the patient's clinical condition, response to treatment, and measure of certain immune aberrations of MG.
Aidong, Liu, Hong, Lin, Yu, Liu, Xinsheng, Cao, Xianni, Wang, Zhuyi, Li   +5 more
openaire   +2 more sources

Muscle strength and fatigue in patients with generalized myasthenia gravis

Muscle & Nerve, 2009
AbstractMyasthenia gravis (MG) is characterized by fatigue and fluctuating muscle weakness resulting from impaired neuromuscular transmission (NMT). The objective of this study was to quantify, by direct measurement of muscle force, the strength and fatigue of patients with MG.
Caitlin J, Symonette, Bradley V, Watson, Wilma J, Koopman, Michael W, Nicolle, Timothy J, Doherty   +4 more
openaire   +2 more sources

Successful treatment of refractory generalized myasthenia gravis with rituximab

European Journal of Neurology, 2009
Objective:  Myasthenia gravis (MG) is an autoimmune neuromuscular disorder for which current therapies carry a high risk of side‐effects and may be insufficient in stabilizing the clinical status. Many therapeutic options can be ruled, such as thymectomy, corticosteroids, azathioprine, cyclophosphamide, mycophenolate mofetil, methotrexate, intravenous ...
C, Lebrun, V, Bourg, N, Tieulie, P, Thomas   +3 more
openaire   +2 more sources

Generalized Myasthenia Gravis

Neurologic Clinics, 2018
Michael K. Hehir, Nicholas J. Silvestri
openaire   +1 more source

Development of Generalized Myasthenia Gravis in Patients With Ocular Myasthenia Gravis

Archives of Neurology, 2003
T. H. Papapetropoulos, J. Ellul, E. Tsibri   +2 more
openaire   +1 more source